(Q44157915)

30 November 2017

The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs (English)

1 reference

30 November 2017

1 reference

Toshimi Michigami

1

1 reference

30 November 2017

Toru Hiraga

2

1 reference

30 November 2017

Paul J Williams

3

1 reference

30 November 2017

Maria Niewolna

4

1 reference

30 November 2017

Riko Nishimura

5

1 reference

30 November 2017

Gregory R Mundy

6

1 reference

30 November 2017

Toshiyuki Yoneda

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Breast Cancer Research and Treatment

30 November 2017

1 reference

30 November 2017

75

1 reference

30 November 2017

249-258

1 reference

30 November 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1019905111666

30 November 2017

0 references

cites work

Bisphosphonates: mechanisms of action

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Bisphosphonates as anticancer drugs

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Breast tumor cell lines from pleural effusions

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

The incidence of metastases in adrenal glands and ovaries removed for carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Current options in treatment of anthracycline-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1019905111666

7 January 2021

Identifiers

DOI

10.1023/A:1019905111666

1 reference

Dimensions Publication ID

30 November 2017

0 references

1 reference